secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2023-01-25T23:59:59+00:00
Accession:  0001628280-23-001516
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott Q4 sales $10.1B, full-year GAAP EPS $3.91; guides FY23 adj. EPS $4.30-4.50
--------------------------------------------------------------------------------

- Q4 GAAP diluted EPS $0.59; adjusted diluted EPS $1.03; full-year GAAP EPS $3.91, adjusted $5.34.
- Full-year sales flat at $43.7B; organic growth 6.4%; COVID-testing sales $8.4B vs. $7.7B in 2021.
- 2023 guidance: GAAP EPS $3.05-3.25, adjusted EPS $4.30-4.50; organic growth ex-COVID high-single digits.
- Quarterly dividend of $0.51 per share declared, payable Feb. 15, 2023; 51 consecutive years of increases.
- FreeStyle Libre Q4 sales ~$1.1B; U.S. growth >40%; FDA approvals for Navitor TAVI and Eterna SCS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000162828023001516/0001628280-23-001516-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000162828023001516/abt-20230125.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-001516

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer